Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Chugai Seeks Japan OK for Hemlibra in Non-Inhibitor Carriers, New Dosing
April 27, 2018
- Bayer Japan Chief “Disappointed” at PMP Removal for Xarelto, Shows Eagerness for Add’l Indications
April 27, 2018
- Astellas Sales Drop 0.9% due to LLP Sell-Off, Japan Biz Hit by Generic Entry
April 27, 2018
- Otsuka’s Jynarque Earns FDA Nod for ADPKD at Second Attempt
April 26, 2018
- Encorafenib/Binimetinib Combo Filed in Japan: Ono
April 26, 2018
- Jitsubo Aims to Enter Contract-Manufacturing Business for Peptide Drug Substances
April 25, 2018
- Gilteritinib Filed in Japan, US for AML: Astellas
April 25, 2018
- Takeda, Shire Reach Preliminary Deal, Extend Takeover Deadline to May 8
April 25, 2018
- Takeda Makes Fifth Pitch for Shire Buyout as Deadline Looms
April 25, 2018
- Shionogi to Transfer Manufacturing Functions to Dedicated Unit
April 24, 2018
- Eisai Transfers European Prialt Rights to Riemser
April 24, 2018
- Top Court Favors Sandoz in Elplat Patent Suit
April 24, 2018
- Atozet, Zetia-Lipitor Combo, Now Available in Japan after Delay
April 24, 2018
- Dupixent Hits Japan Shelves: Sanofi
April 24, 2018
- Novartis Seeks Japan Approval for Kymriah, Will Outcome-Based Model Be Put in Place?
April 24, 2018
- Japan Ethical Drug Sales in 54 Fields Shrink 1.6% in 2017
April 23, 2018
- Takeda Sweetens Bid for Shire, Ups Cash Component
April 23, 2018
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected
April 20, 2018
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup
April 19, 2018
- Astellas Sells Agensys Research Facilities to Kite
April 19, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…